JP2018521667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521667A5 JP2018521667A5 JP2018504165A JP2018504165A JP2018521667A5 JP 2018521667 A5 JP2018521667 A5 JP 2018521667A5 JP 2018504165 A JP2018504165 A JP 2018504165A JP 2018504165 A JP2018504165 A JP 2018504165A JP 2018521667 A5 JP2018521667 A5 JP 2018521667A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- cell
- antibody
- domain
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 45
- 150000007523 nucleic acids Chemical group 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 239000012636 effector Substances 0.000 claims description 17
- 210000004443 dendritic cell Anatomy 0.000 claims description 12
- 210000002540 macrophage Anatomy 0.000 claims description 12
- 210000001616 monocyte Anatomy 0.000 claims description 12
- 230000000139 costimulatory effect Effects 0.000 claims description 9
- 230000003834 intracellular effect Effects 0.000 claims description 9
- 230000004936 stimulating effect Effects 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 206010057249 Phagocytosis Diseases 0.000 claims description 3
- 230000030741 antigen processing and presentation Effects 0.000 claims description 3
- 230000005889 cellular cytotoxicity Effects 0.000 claims description 3
- 230000008782 phagocytosis Effects 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 238000004520 electroporation Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 3
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 3
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 210000001589 microsome Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021187803A JP7600081B2 (ja) | 2015-07-28 | 2021-11-18 | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
| JP2023077024A JP2023090882A (ja) | 2015-07-28 | 2023-05-09 | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
| JP2025067231A JP2025105634A (ja) | 2015-07-28 | 2025-04-16 | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562197675P | 2015-07-28 | 2015-07-28 | |
| US62/197,675 | 2015-07-28 | ||
| PCT/US2016/044440 WO2017019848A1 (en) | 2015-07-28 | 2016-07-28 | Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021187803A Division JP7600081B2 (ja) | 2015-07-28 | 2021-11-18 | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521667A JP2018521667A (ja) | 2018-08-09 |
| JP2018521667A5 true JP2018521667A5 (enExample) | 2019-09-05 |
| JP7032304B2 JP7032304B2 (ja) | 2022-03-08 |
Family
ID=57885035
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504165A Active JP7032304B2 (ja) | 2015-07-28 | 2016-07-28 | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
| JP2021187803A Active JP7600081B2 (ja) | 2015-07-28 | 2021-11-18 | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
| JP2023077024A Pending JP2023090882A (ja) | 2015-07-28 | 2023-05-09 | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
| JP2025067231A Pending JP2025105634A (ja) | 2015-07-28 | 2025-04-16 | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021187803A Active JP7600081B2 (ja) | 2015-07-28 | 2021-11-18 | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
| JP2023077024A Pending JP2023090882A (ja) | 2015-07-28 | 2023-05-09 | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
| JP2025067231A Pending JP2025105634A (ja) | 2015-07-28 | 2025-04-16 | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (13) | US11034749B2 (enExample) |
| EP (1) | EP3328402A4 (enExample) |
| JP (4) | JP7032304B2 (enExample) |
| KR (2) | KR20240132100A (enExample) |
| CN (2) | CN115747168A (enExample) |
| AU (3) | AU2016298229B2 (enExample) |
| BR (1) | BR112018001858B1 (enExample) |
| HK (1) | HK1256141A1 (enExample) |
| IL (4) | IL292507B2 (enExample) |
| MX (2) | MX393707B (enExample) |
| RU (1) | RU2766690C2 (enExample) |
| WO (1) | WO2017019848A1 (enExample) |
| ZA (1) | ZA201800611B (enExample) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| US10434153B1 (en) | 2015-05-20 | 2019-10-08 | Kim Leslie O'Neill | Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors |
| US11034749B2 (en) * | 2015-07-28 | 2021-06-15 | The Trustees Of The University Of Pennsylvania | Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof |
| US11352439B2 (en) | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
| US10525082B2 (en) | 2015-09-09 | 2020-01-07 | Seattle Children's Hospital | Genetic engineering of macrophages for immunotherapy |
| CN108137704A (zh) * | 2015-10-13 | 2018-06-08 | 迅雷生物科技有限公司 | 免疫疗法中的巨噬细胞car（moto-car） |
| US10875919B2 (en) * | 2016-04-26 | 2020-12-29 | Alector Llc | Chimeric receptors and methods of use thereof |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CA3035080A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| CN107286246B (zh) * | 2016-12-28 | 2019-12-17 | 时力生物科技（北京）有限公司 | 治疗脑胶质瘤的嵌合抗原受体修饰的树突状细胞及其制备方法 |
| ES2988795T3 (es) | 2017-02-27 | 2024-11-21 | Juno Therapeutics Inc | Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular |
| US10415017B2 (en) * | 2017-05-17 | 2019-09-17 | Thunder Biotech, Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
| AU2017414703B2 (en) * | 2017-05-17 | 2025-02-06 | Thunder Biotech Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
| KR20200054160A (ko) * | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| JP7286658B2 (ja) * | 2017-09-26 | 2023-06-05 | セロ・セラピューティクス・インコーポレイテッド | キメラエンガルフメント受容体分子および使用方法 |
| WO2019089855A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| SG11202005217VA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Phenotypic markers for cell therapy and related methods |
| CN118512596A (zh) * | 2017-12-27 | 2024-08-20 | 武田药品工业株式会社 | 含核酸脂质纳米粒子及其用途 |
| CN108047332B (zh) * | 2018-01-15 | 2021-08-24 | 阿思科力(苏州)生物科技有限公司 | 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用 |
| AU2019215110B2 (en) * | 2018-02-02 | 2024-07-25 | The Trustees Of The University Of Pennsylvania | Modified monocytes/macrophages/dendritic cells expressing chimeric antigen receptors and uses in diseases and disorders associated with protein aggregates |
| US11813292B2 (en) * | 2018-03-12 | 2023-11-14 | Immunity Bio, Inc. | Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity) |
| US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
| EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| WO2019191332A1 (en) * | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases |
| WO2019191339A1 (en) * | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof |
| AU2019243154A1 (en) | 2018-03-28 | 2020-10-01 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
| GB201807945D0 (en) | 2018-05-16 | 2018-06-27 | Ospedale San Raffaele Srl | Vector production |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| WO2020016897A1 (en) | 2018-07-19 | 2020-01-23 | Oncohost Ltd | Il-31 improves efficacy of macrophage-based adoptive cell therapy for cancer |
| CN112840211B (zh) * | 2018-08-27 | 2024-11-12 | 南特生物公司 | Rp182组合物及方法 |
| TW202016295A (zh) | 2018-08-31 | 2020-05-01 | 日商諾伊爾免疫生物科技股份有限公司 | Car表現t細胞及car表現載體 |
| US20220119476A1 (en) * | 2018-08-31 | 2022-04-21 | The Trustees Of The University Of Pennsylvania | Activation of Antigen Presenting Cells and Methods for Using the Same |
| CN111004781A (zh) * | 2018-10-08 | 2020-04-14 | 南加利福尼亚大学 | 长期扩增粒细胞-巨噬细胞祖细胞的方法及其应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| WO2020160217A1 (en) * | 2019-02-01 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Microenvironment sensors to regulate engineered gene expression |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| US12018061B2 (en) * | 2019-03-08 | 2024-06-25 | St Phi Therapeutics Co., Ltd. | Chimeric endocytic receptors and method of use thereof |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| BR112021021843A8 (pt) * | 2019-04-30 | 2022-06-21 | Myeloid Therapeutics Inc | Composições de proteínas de fusão quiméricas modificadas e método de uso das mesmas |
| KR20220038020A (ko) * | 2019-05-29 | 2022-03-25 | 오르비스 헬스 솔루션즈 엘엘씨 | 키메라 수용체를 발현하기 위한 전달 벡터 및 입자 및 그의 사용 방법 |
| JP7620548B2 (ja) | 2019-06-26 | 2025-01-23 | 武田薬品工業株式会社 | トランスフェクション方法 |
| AU2020316867A1 (en) * | 2019-07-19 | 2022-03-03 | Institut Gustave Roussy | P21 expressing monocytes for cancer cell therapy |
| CN118165120A (zh) * | 2019-07-22 | 2024-06-11 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体及其应用 |
| WO2021019706A1 (ja) * | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Ｃａｒ発現免疫細胞を含む細胞集団の製造方法 |
| CN114981409A (zh) | 2019-09-03 | 2022-08-30 | 美洛德生物医药公司 | 用于基因组整合的方法和组合物 |
| CN114502781B (zh) | 2019-09-20 | 2025-06-17 | 纳维再生科技股份有限公司 | 个人化癌症免疫治疗 |
| KR102498546B1 (ko) * | 2019-09-27 | 2023-02-09 | 한국생명공학연구원 | 항체를 분비하는 대식세포의 제조방법 및 이를 이용한 항암치료 기술 |
| KR20220143642A (ko) * | 2019-12-11 | 2022-10-25 | 마이얼로이드 테라퓨틱스, 인크. | 치료 세포 조성물 및 그의 제조 방법 및 용도 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN110954701B (zh) * | 2019-12-18 | 2023-07-21 | 重庆医科大学 | 一种肝纤维化或肝硬化的诊断试剂盒 |
| CN113106067B (zh) * | 2020-01-10 | 2024-06-21 | 南京大学 | 一种嵌合抗原受体-单核/巨噬细胞(car-m)的构建及其应用 |
| EP4431110A3 (en) * | 2020-01-19 | 2025-01-15 | Chineo Medical Technology Co., Ltd. | Enhanced receptor for improving immune cell function |
| US20240261329A1 (en) * | 2020-02-13 | 2024-08-08 | Sichuan University | Chimeric antigen receptor and use thereof |
| WO2021180215A1 (en) * | 2020-03-12 | 2021-09-16 | Nanjing Legend Biotech Co., Ltd. | Glypican-2-binding moieties, chimeric antigen receptors and uses thereof |
| EP4146805A2 (en) * | 2020-05-05 | 2023-03-15 | ARO Biotherapeutics Company | Prostate specific membrane antigen binding fibronectin type iii domains and cells comprising the same |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
| WO2021248061A1 (en) | 2020-06-04 | 2021-12-09 | Carisma Therapeutics Inc. | Novel constructs for chimeric antigen receptors |
| CN111840324B (zh) * | 2020-06-16 | 2023-05-12 | 上海市第一人民医院 | 应用于骨肉瘤细胞成像或治疗的Au DENPs-巨噬细胞复合物 |
| CN116113422A (zh) * | 2020-06-26 | 2023-05-12 | 凯瑞斯马治疗公司 | 免疫细胞的mRNA转染 |
| CN111925448B (zh) * | 2020-08-03 | 2022-06-21 | 山东大学 | 在体生成car-巨噬细胞的制备方法及肿瘤免疫治疗中的应用 |
| GB202014920D0 (en) | 2020-09-22 | 2020-11-04 | Unikum Therapeutics Aps | Methods for treating cancer and autoimmune and inflammatory diseases |
| WO2022066757A1 (en) * | 2020-09-23 | 2022-03-31 | Myeloid Therapeutics, Inc. | Improved methods and compositions for expression of nucleic acids in cells |
| EP4240367A4 (en) | 2020-11-04 | 2024-10-16 | Myeloid Therapeutics, Inc. | MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| CN112830974B (zh) * | 2021-01-08 | 2022-07-26 | 深圳市珈钰生物科技有限公司 | 一种嵌合抗原受体、载体、人树突状细胞、细胞系、实体肿瘤治疗药物及制备方法和应用 |
| EP4279596A4 (en) * | 2021-01-15 | 2025-01-22 | National University Corporation Tokai National Higher Education and Research System | CHIMERIC TARGET FACTOR RECEPTOR |
| WO2022186625A1 (ko) * | 2021-03-03 | 2022-09-09 | 서울대학교산학협력단 | 키메릭 항원 수용체-대식 세포의 제조 방법 및 그 세포의 용도 |
| CA3212398A1 (en) | 2021-03-17 | 2022-09-22 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| KR20220131801A (ko) | 2021-03-22 | 2022-09-29 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| WO2022203226A1 (ko) * | 2021-03-22 | 2022-09-29 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| WO2022203227A1 (ko) * | 2021-03-23 | 2022-09-29 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR20220132401A (ko) | 2021-03-23 | 2022-09-30 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR20220136876A (ko) | 2021-04-01 | 2022-10-11 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| WO2022211376A1 (ko) * | 2021-04-01 | 2022-10-06 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| WO2022215920A1 (ko) * | 2021-04-06 | 2022-10-13 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| CN114934071B (zh) * | 2021-04-30 | 2023-10-17 | 四川大学华西医院 | 一种表达免疫调节因子的car载体及其应用 |
| CA3218780A1 (en) | 2021-05-11 | 2022-11-17 | Daniel Getts | Methods and compositions for genomic integration |
| EP4340871A4 (en) * | 2021-05-19 | 2025-05-21 | University of Southern California | Chimeric antigen receptor-modified granulocyte macrophage precursors for cancer immunotherapy |
| CN113321743B (zh) * | 2021-07-02 | 2022-10-21 | 海南精准医疗科技有限公司 | 一种靶向赖氨酰氧化酶1的嵌合抗原受体及其用途 |
| KR20230089462A (ko) * | 2021-12-13 | 2023-06-20 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR20230089464A (ko) * | 2021-12-13 | 2023-06-20 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| CN114410588B (zh) * | 2022-01-29 | 2022-11-04 | 西安电子科技大学 | 一种α1β1整合素依赖增强型CAR巨噬细胞及其制备方法和应用 |
| CN114657143B (zh) * | 2022-03-11 | 2022-10-25 | 西安电子科技大学 | 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用 |
| JP2025511383A (ja) | 2022-04-07 | 2025-04-15 | アンスティテュ キュリィ | キメラ抗原受容体で改変された骨髄系細胞及び抗がん治療のためのその使用 |
| JP2025514646A (ja) | 2022-04-07 | 2025-05-09 | アンスティテュ キュリィ | Ｃｄ４０を有するキメラ抗原受容体で改変された骨髄系細胞及び抗がん治療のためのその使用 |
| CA3247582A1 (en) * | 2022-04-18 | 2023-10-26 | Wisconsin Alumni Research Foundation | COMBINATIONAL IMMUNOTHERAPIES INVOLVING CAR-M, CAR-NK, CAR-EOS AND CAR-N CELLS |
| CN118178626A (zh) * | 2022-04-29 | 2024-06-14 | 苏州易慕峰生物科技有限公司 | 抗原递呈细胞及car-t细胞联合在抗肿瘤中的应用 |
| GB202208605D0 (en) | 2022-06-13 | 2022-07-27 | Unikum Therapeutics Aps | Engineered immune cells |
| EP4570905A1 (en) * | 2022-08-09 | 2025-06-18 | Agc Inc. | Method for producing proliferative macrophage-like cells (pmac) |
| CN120676959A (zh) * | 2022-12-21 | 2025-09-19 | 苏黎世大学 | 用于巨噬细胞极化的方法 |
| CN115957335B (zh) * | 2023-01-03 | 2024-05-28 | 华中科技大学同济医学院附属协和医院 | 基于嵌合抗原受体修饰的单核细胞外囊泡类似物、制备方法及应用 |
| CN116218786B (zh) * | 2023-03-09 | 2024-01-23 | 山东大学齐鲁医院 | 一种多重基因编辑的通用型巨噬细胞及在制备抗肿瘤药物中的应用 |
| CN116380580A (zh) * | 2023-03-15 | 2023-07-04 | 中国人民解放军空军军医大学 | 一种血浆检测前处理方法 |
| WO2024210160A1 (en) | 2023-04-07 | 2024-10-10 | Takeda Pharmaceutical Company Limited | Conjugation complex |
| EP4483866A1 (en) | 2023-06-28 | 2025-01-01 | Makrolife Biotech GmbH | Pharmaceutical compositions for the treatment or prevention of cancer |
| CN120005830A (zh) * | 2023-11-06 | 2025-05-16 | 复星凯瑞(上海)生物科技有限公司 | 一种分泌cd47-pd-l1的基因修饰的免疫细胞的制备及应用 |
| GB202318553D0 (en) | 2023-12-05 | 2024-01-17 | Unikum Therapeutics Aps | Engineered plasmacytoid dendritic cells |
| CN118059217B (zh) * | 2023-12-20 | 2025-02-28 | 西安电子科技大学 | 一种表观遗传药物联合过继单核/巨噬细胞免疫治疗在制备肿瘤疾病生物药品中的应用 |
| CN118206664A (zh) * | 2024-02-04 | 2024-06-18 | 中国科学院杭州医学研究所 | 原位生成多功能嵌合抗原受体巨噬细胞的方法及其在免疫治疗中的应用 |
| CN118685362A (zh) * | 2024-05-15 | 2024-09-24 | 西安电子科技大学 | 一种癌环境响应型的过继单核或巨噬细胞免疫治疗生物制品及其在抗肿瘤中的应用 |
| WO2026016944A1 (zh) * | 2024-07-15 | 2026-01-22 | 南京元迈细胞生物科技有限公司 | 腺病毒载体及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3334764A (en) | 1966-10-25 | 1967-08-08 | John P Fouser | Infant nurser |
| US20040053837A1 (en) | 1998-09-30 | 2004-03-18 | Ludwig Institute For Cancer Research | Composition and method for modulating vasculogenesis or angiogenesis |
| CA2425862C (en) * | 2000-11-07 | 2013-01-22 | City Of Hope | Cd19-specific redirected immune cells |
| WO2003070905A2 (en) * | 2002-02-15 | 2003-08-28 | Zycos, Inc. | Electroporation methods for introducing bioactive agents into cells |
| WO2006036445A2 (en) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
| CN101072879B (zh) * | 2004-10-13 | 2011-05-11 | 克鲁塞尔荷兰公司 | 改良的腺病毒载体及其应用 |
| KR101253363B1 (ko) | 2004-10-13 | 2013-04-15 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 개선된 아데노바이러스 벡터 및 그것의 용도 |
| RU2433825C2 (ru) | 2004-12-06 | 2011-11-20 | Медисинова, Инк. | Способ лечения невропатической боли и связанных с ней синдромов |
| JP4604892B2 (ja) | 2005-07-15 | 2011-01-05 | 船井電機株式会社 | 情報記録／再生装置 |
| FR2888850B1 (fr) * | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| JP2010519313A (ja) * | 2007-02-23 | 2010-06-03 | ベイラー リサーチ インスティテュート | Ｃｌｅｃ−６を介したヒト抗原提示細胞の活性化 |
| JP5779090B2 (ja) | 2008-04-09 | 2015-09-16 | マックスサイト インコーポレーティッド | 新規に単離された細胞の治療組成物の操作および送達 |
| SG10201914001QA (en) * | 2010-02-25 | 2020-03-30 | Abt Holding Co | Modulation of macrophage activation |
| EP2558109A4 (en) | 2010-04-16 | 2014-09-24 | Bellicum Pharmaceuticals Inc | METHOD FOR TREATING HARD TUMORS |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP6053688B2 (ja) * | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| JP6021617B2 (ja) | 2012-12-05 | 2016-11-09 | カンタツ株式会社 | 撮像レンズ |
| US9221908B2 (en) * | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| ES2814962T3 (es) | 2013-02-20 | 2021-03-29 | Novartis Ag | Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123 |
| EP2970985A1 (en) | 2013-03-14 | 2016-01-20 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| DE102013215794A1 (de) | 2013-08-09 | 2015-02-12 | Krones Ag | Vorrichtung und Verfahren zum Ausrichten von unrunden Behältern |
| GB201315036D0 (en) | 2013-08-22 | 2013-10-02 | Renishaw Plc | Apparatus and method for building objects by selective solidification of powder material |
| ES3034398T3 (en) | 2014-08-28 | 2025-08-18 | Bioatla Inc | Conditionally active chimeric antigen receptors for modified t-cells |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| US9777064B2 (en) | 2015-03-17 | 2017-10-03 | Chimera Bioengineering, Inc. | Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof |
| US20180355318A1 (en) | 2015-04-29 | 2018-12-13 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| CN104829733B (zh) * | 2015-05-25 | 2018-06-05 | 广州百暨基因科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
| GB201509413D0 (en) | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| US20170216354A1 (en) | 2015-06-12 | 2017-08-03 | Batu Biologics, Inc. | Clinically useful non-antigen pulsed dendritic cells |
| US11034749B2 (en) * | 2015-07-28 | 2021-06-15 | The Trustees Of The University Of Pennsylvania | Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof |
| CN108137704A (zh) | 2015-10-13 | 2018-06-08 | 迅雷生物科技有限公司 | 免疫疗法中的巨噬细胞car（moto-car） |
| WO2021248061A1 (en) * | 2020-06-04 | 2021-12-09 | Carisma Therapeutics Inc. | Novel constructs for chimeric antigen receptors |
-
2016
- 2016-07-28 US US15/747,555 patent/US11034749B2/en active Active
- 2016-07-28 CN CN202211374453.1A patent/CN115747168A/zh active Pending
- 2016-07-28 KR KR1020247027659A patent/KR20240132100A/ko active Pending
- 2016-07-28 RU RU2018107047A patent/RU2766690C2/ru active
- 2016-07-28 CN CN201680054514.2A patent/CN108025024B/zh active Active
- 2016-07-28 MX MX2018001182A patent/MX393707B/es unknown
- 2016-07-28 AU AU2016298229A patent/AU2016298229B2/en active Active
- 2016-07-28 KR KR1020187005871A patent/KR102697827B1/ko active Active
- 2016-07-28 WO PCT/US2016/044440 patent/WO2017019848A1/en not_active Ceased
- 2016-07-28 HK HK18115222.8A patent/HK1256141A1/zh unknown
- 2016-07-28 EP EP16831340.1A patent/EP3328402A4/en active Pending
- 2016-07-28 IL IL292507A patent/IL292507B2/en unknown
- 2016-07-28 JP JP2018504165A patent/JP7032304B2/ja active Active
- 2016-07-28 IL IL315940A patent/IL315940A/en unknown
- 2016-07-28 IL IL297905A patent/IL297905A/en unknown
- 2016-07-28 BR BR112018001858-9A patent/BR112018001858B1/pt active IP Right Grant
-
2018
- 2018-01-14 IL IL256892A patent/IL256892B/en unknown
- 2018-01-26 MX MX2022008288A patent/MX2022008288A/es unknown
- 2018-01-29 ZA ZA2018/00611A patent/ZA201800611B/en unknown
-
2020
- 2020-04-24 US US16/858,183 patent/US11306133B2/en active Active
-
2021
- 2021-09-16 US US17/477,436 patent/US11319358B2/en active Active
- 2021-09-16 US US17/477,206 patent/US11407805B2/en active Active
- 2021-09-16 US US17/477,485 patent/US11306134B2/en active Active
- 2021-09-16 US US17/477,114 patent/US11359002B2/en active Active
- 2021-09-16 US US17/477,461 patent/US20220033467A1/en not_active Abandoned
- 2021-09-16 US US17/477,475 patent/US11325963B2/en active Active
- 2021-09-16 US US17/477,057 patent/US20220033465A1/en not_active Abandoned
- 2021-09-16 US US17/477,448 patent/US11332511B2/en active Active
- 2021-11-18 JP JP2021187803A patent/JP7600081B2/ja active Active
-
2022
- 2022-03-10 US US17/691,842 patent/US11498954B2/en active Active
- 2022-10-06 US US17/938,501 patent/US20230279074A1/en not_active Abandoned
- 2022-11-01 AU AU2022263479A patent/AU2022263479B2/en active Active
-
2023
- 2023-05-09 JP JP2023077024A patent/JP2023090882A/ja active Pending
-
2025
- 2025-02-24 US US19/061,415 patent/US20260008833A1/en active Pending
- 2025-04-16 JP JP2025067231A patent/JP2025105634A/ja active Pending
-
2026
- 2026-01-10 AU AU2026200155A patent/AU2026200155A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521667A5 (enExample) | ||
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| CN114761438A (zh) | 用于编程细胞外囊泡的重组多肽 | |
| JP2020508329A5 (enExample) | ||
| JP2017507936A5 (enExample) | ||
| CN110461357A (zh) | 抗cd16a抗体与细胞因子的组合 | |
| WO2016154621A1 (en) | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF | |
| JP2016509582A5 (enExample) | ||
| JP2012100677A5 (enExample) | ||
| JP2014509841A5 (enExample) | ||
| JP2016538297A5 (enExample) | ||
| JP2019520034A5 (enExample) | ||
| CN111615518B (zh) | 阻断emt途径并克服癌干细胞的il8 | |
| CN113646328A (zh) | 一种免疫细胞因子及其制备与用途 | |
| JP7560365B2 (ja) | 抗ｐｄ－ｌ１ワクチン組成物 | |
| CN108367068A (zh) | 用于治疗白血病的抗-s100a8 | |
| JP2016529213A5 (enExample) | ||
| WO2017002919A1 (ja) | 抗プレキシンａ１アゴニスト抗体 | |
| US20240374644A1 (en) | Herv-k antibody therapeutics | |
| CN116157139A (zh) | 免疫调节复合物及其用于治疗的用途 | |
| AU2020387199A1 (en) | Composition for preventing or treating cancer, comprising anti-CD300C monoclonal antibodies | |
| JP2021516992A (ja) | 抗ｐｄ−１ワクチン組成物 | |
| KR102809807B1 (ko) | 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법 | |
| JP2024517985A (ja) | 抗－ＣＤ３００ｃモノクローナル抗体及びその癌の予防または治療用バイオマーカー | |
| US12497464B1 (en) | Antibody, antibody fragments or peptide for treating cancer and methods of formation and administration |